IO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
On September 6, 2022, IO Biotech (Nasdaq: IOBT) announced that President and CEO Mai-Britt Zocca will participate in a fireside chat and investor meetings at the Morgan Stanley 20th Annual Global Healthcare Conference from September 12 to 14, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On September 6, 2022, IO Biotech (Nasdaq: IOBT) announced that President and CEO Mai-Britt Zocca will participate in a fireside chat and investor meetings at the Morgan Stanley 20th Annual Global Healthcare Conference from September 12 to 14, 2022. The fireside chat is scheduled for September 14 at 8:35 a.m. ET. Investors can access the webcast via the provided link, and a replay will be available for 180 days on the company’s website. IO Biotech is focused on developing immune-modulating cancer therapies using its T-win® technology platform.
Details
News Market Reaction – IOBT
The recorded move for IOBT in the trading session of this news was -4.97%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that Mai-Britt Zocca, the company’s President and CEO, will be participating in a fireside chat and investor meetings at the Morgan Stanley 20th Annual Global Healthcare Conference, taking place September 12 – 14, 2022.
Fireside Chat Details
Date and Time: Wednesday, September 14, 2022 at 8:35 a.m. ET
Presenter: Mai-Britt Zocca, President & CEO
Webcast Link: Here
A webcast replay of the presentation will be available from the Investors section of the Company’s website at www.iobiotech.com for 180 days.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform. The T-win® platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. IO Biotech is advancing in clinical studies its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, and through clinical and preclinical development its other pipeline candidates. IO Biotech is headquartered in Copenhagen, Denmark and has additional offices within the United States (New York, New York and Rockville, Maryland) and United Kingdom (Monmouthshire).
For further information, please visit www.iobiotech.com.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding future clinical trials and results, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Company Contact:
Mai-Britt Zocca, Ph.D.
President and CEO
IO Biotech, Inc.
mz@iobiotech.com
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com
Media Contact:
Raena Mina, Ph.D.
LifeSci Communications
646-606-1438
rmina@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.